A Retrospective Swedish Cohort Study on Health Outcomes, Life Expectancy, Resource Use and Costs in Patients With a History of Myocardial Infarction and Additional Risk Factors for Atherothrombosis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 100,000
- 试验地点
- 1
- 主要终点
- Assessment of the burden of illness among high risk patients with a history of MI
研究概览
简要总结
To characterize and estimate the size of different populations with a history of acute coronary syndrome in Sweden. To assess the burden of illness (co-morbidities, mortality rates healthcare resource utilization and atherothrombotic events) among patients with a history of myocardial infarction (MI) 1-3 years ago and additional risk factors for atherothrombosis.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients hospitalised for ACS between 01.07.2006 and 31.06.2011.
排除标准
- •Not applicable
结局指标
主要结局
Assessment of the burden of illness among high risk patients with a history of MI
时间窗: Follow up period 1-7 years
1. Describe patients' demographics and clinical characteristics 2. Assess rate of CV event (MI and stroke), CV mortality and all cause mortality 3. Assess rate of CV events (MI and stroke), CV mortality and all cause mortality in patients having at least 24 months and 36 months without MI, respectively 4. Assess the impact of additional atherothrombotic risk factors 5. Describe treatment patterns 6. Evaluate healthcare resource use and costs 7. Assess predictors of new CV events (MI and stroke), CV mortality and all cause mortality
Description of study population in terms of death, cardiovascular disease events and health care resource utilization
时间窗: Follow up period 1-7 years
1. Death (all cause and CVD death) 2. CVD event (MI or Stroke) 3. Health care resource use and costs.
Assessment of the mortality rates among high risk patients with a history of MI
时间窗: Follow up period 1-7 years
1. Describe patients' demographics and clinical characteristics 2. Assess rate of CV event (MI and stroke), CV mortality and all cause mortality 3. Assess rate of CV events (MI and stroke), CV mortality and all cause mortality in patients having at least 24 months and 36 months without MI, respectively 4. Assess the impact of additional atherothrombotic risk factors 5. Describe treatment patterns 6. Evaluate healthcare resource use and costs 7. Assess predictors of new CV events (MI and stroke), CV mortality and all cause mortality
次要结局
- Description of the high risk patient population in terms of CVD events, bleedings and co-morbidities.(Follow up period 1-7 years)